中国当代医药
中国当代医药杂志欢迎您 今天是   2025年4月5日星期六
设为首页  加入收藏  联系我们         
 
      首 页    |    本刊简介     |    期刊荣誉     |    编采团队     |    会务培训     |    理事单位     |    下载专区     |    在线留言     |    联系我们     |     返回中国当代医药网
中国当代医药  2024, Vol. 31 Issue (13): 15-18转23    
  论著 本期目录 | 过刊浏览 | 高级检索 |
疏血通注射液治疗缺血性脑卒中的效果评价
邓永雄1 毕海权2
1.重庆市永川惠民中医医院内科,重庆 402171;
2.重庆医药高等专科学校附属第一医院综合病区,重庆 402160
Effect evaluation of Shuxuetong Injection in the treatment of ischemic stroke
DENG Yongxiong1 BI Haiquan2
1.Department of Internal Medicine,Yongchuan Huimin Traditional Chinese Medicine Hospital,Chongqing 402171,China;
2.General Ward,the First Affiliated Hospital of Chongqing Medical and Pharmaceutical College,Chongqing 402160,China
全文: PDF (873 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的 探讨疏血通注射液治疗缺血性脑卒中的效果。方法 选取2019 年1 月至2023 年5 月重庆市永川惠民中医医院收治的49例缺血性脑卒中患者作为研究对象,按照随机数字表法将其分为对照组(24例)与观察组(25例),对照组采用阿司匹林与氯吡格雷治疗,观察组在对照组治疗方法的基础上加用疏血通注射液治疗。比较两组患者的临床疗效及治疗期间出血发生情况,并比较两组治疗前后的凝血功能及疾病相关评分。结果 观察组治疗后的总有效率高于对照组,出血总发生率低于对照组,差异有统计学意义(P<0.05)。两组患者治疗后的活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)均长于本组治疗前,国际标准化比值(INR)、Barthel 指数(BI)评分均高于本组治疗前,D-二聚体(D-D)水平、美国国立卫生院卒中量表(NIHSS)评分、中医症状积分均低于本组治疗前,差异有统计学意义(P<0.05)。观察组患者治疗后的APTT、PT 均长于对照组,INR 值高于对照组,D-D 水平、NIHSS 评分、中医症状积分均低于对照组,差异有统计学意义(P<0.05)。结论 疏血通注射液治疗缺血性脑卒中能有效提升临床疗效,对患者凝血功能和神经功能进行改善,降低出血发生率,并提升患者日常生活能力。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 缺血性脑卒中疏血通注射液凝血功能出血转化    
Abstract:Objective To explore the effect of Shuxuetong Injection in the treatment of ischemic stroke.Methods From January 2019 to May 2023,a total of 49 patients with ischemic stroke in Yongchuan Huimin Traditional Chinese Medicine Hospital of Chongqing City were selected as the research objects,and they were divided into control group (24 cases) and observation group (25 cases) according to random number table method.The control group were treated with Aspirin and Clopidogrel,while the observation group were treated with Shuxuetong Injection on the basis of the treatment of the control group.The clinical efficacy and the incidence of bleeding during treatment were compared between the two groups,and the coagulation function and disease-related scores before and after treatment were compared between the two groups.Results After treatment,the total effective rate of the observation group was higher than that of the control group,and the total incidence of bleeding was lower than that of the control group,and the differences were statistically significant (P<0.05).After treatment,the activated partial thromboplastin time (APTT)and prothrombin time (PT)of the two groups were longer than those before treatment,the international normalized ratio (INR) and Barthel index (BI) score of the two groups were higher than those before treatment,the D-dimer(D-D)level,the national institutes of health stroke scale(NIHSS)score and the traditional Chinese medicine symptom score of the two groups were lower than those before treatment,and the differences were statistically significant (P<0.05).After treatment,the APTT and PT of the observation group were longer than those of the control group,the INR value and BI score of the observation group were higher than those of the control group,and the D-D level,the NIHSS score and the traditional Chinese medicine symptom score of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).Conclusion Shuxuetong Injection can effectively improve the clinical efficacy,improve the coagulation function and neurological function,reduce the incidence of bleeding and improve the daily living ability of patients.
Key wordsIschemic stroke    Shuxuetong Injection    Coagulation function    Hemorrhagic transformation
    
引用本文:   
邓永雄1; 毕海权2. 疏血通注射液治疗缺血性脑卒中的效果评价[J]. 中国当代医药, 2024, 31(13): 15-18转23.
DENG Yongxiong1 BI Haiquan2. Effect evaluation of Shuxuetong Injection in the treatment of ischemic stroke. 中国当代医药, 2024, 31(13): 15-18转23.
链接本文:  
https://www.dangdaiyiyao.com/CN/     或     https://www.dangdaiyiyao.com/CN/Y2024/V31/I13/15
中华人民共和国互联网药品信息服务资格证书(京)-非经营性-2016-0092
京ICP备11001767号-6  京公网安备 11010502046607号  互联网药品信息服务资格证  期刊出版许可证  广告经营许可证
信息产业部备案管理系统网址 http://beian.miit.gov.cn/state/outPortal/loginPortal.action
投稿热线:010-59626690 总机:010-59626692/18/19/20   传真:010-59626204   投稿信箱:ddyy@vip.163.com
地址:北京市朝阳区东四环中路78号楼(大成国际中心B1座)8B02室   邮编:100124
技术支持:北京玛格泰克科技发展有限公司
Copyright 2000-2014 版权所有 《中国当代医药》杂志社 未经授权请勿转载